Temozolomide as salvage treatment in primary brain lymphomas

M Reni, F Zaja, W Mason, J Perry, E Mazza, M Spina, R Bordonaro, F Ilariucci, M Faedi, G Corazzelli, P Manno, E Franceschi, A Pace, M Candela, A Abbadessa, C Stelitano, G Latte, A J M Ferreri, M Reni, F Zaja, W Mason, J Perry, E Mazza, M Spina, R Bordonaro, F Ilariucci, M Faedi, G Corazzelli, P Manno, E Franceschi, A Pace, M Candela, A Abbadessa, C Stelitano, G Latte, A J M Ferreri

Abstract

Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent chemotherapy is superior to MTX alone. Treatment options for patients with recurrent primary brain lymphoma are limited; there is no standard second-line chemotherapy. New chemotherapeutic agents with clear activity in brain lymphoma are needed for treatment of recurrent disease. We report the results of a phase II trial assessing activity of the alkylating agent temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-containing chemotherapy and/or radiotherapy. A median of two courses (range 1-12) of temozolomide 150 mg m-2 day-1, for 5 days every 4 weeks was administered to 36 patients yielding nine complete and two partial responses (response rate: 31%; 95% confidence interval 16-46%). One-year survival was 31% (95% confidence interval 16-46%). Toxicity was negligible. We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment.

References

    1. Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, Van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international Workshop to Standardize Baseline Evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23: 5034–5043
    1. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70: 219–224
    1. Enting RH, Demopoulos A, DeAngelis LM, Abrey L (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63: 901–903
    1. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2003) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15 2002. J Clin Oncol 21: 2407–2414
    1. Ferreri AJM, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY, for the International Extranodal Lymphoma Study Group (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513–1520
    1. Ferreri AJM, Reni M, Villa E (2000) Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 11: 927–937
    1. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, martus P, Korfel A (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17(7): 1141–1145
    1. MacDonald DR, Cascino TL, Schold Jr SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant gliomas. J Clin Oncol 8: 1277–1280
    1. Reni M, Ferreri AJ (2004a) Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol 22: 1165–1167
    1. Reni M, Ferreri AJM, Villa E (1999) Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79: 530–534
    1. Reni M, Ferreri AJM, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8: 227–234
    1. Reni M, Mason W, Zaja F, Perry J, Franceshi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM (2004b) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40: 1682–1688
    1. Tyson RM, Siegal T, Doolittle ND, Lacy C, Kraemer DF, Neutwelt EA (2003) Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymph 44: 627–633

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner